TransEnterix, Inc. operates as a development stage medical device company. The company is focused on the development and commercialization of SurgiBot™, a novel patient side minimally invasive surgical robotic system. It uses flexible instruments and robotics to improve the outcomes of minimally invasive surgery. The company was formerly known as SafeStitch Medical, Inc. after merger it has changed its name to TransEnterix, Inc. TransEnterix was founded in August 1988 and is headquartered in Morrisville, NC.
TRXC has finalized its design for the SurgiBot and will submit the device for FDA(510)k clearance in Q4 of 2014, expecting approval and commercialization in mid 2015.
The SurgiBot will retail for $500,000, and will be the first surgical robot on the market to compete with Intuitive Surgical's Da Vinci System for a fraction of the price.
The SurgiBot has 100% tactile feedback, a huge feature that all surgeons look for when conducting surgery. TransEnterix's competitors, like TITXF, who is still far behind in the development of their SPORT system when compared to TransEnterix, has zero tactile and zero haptic feedback.
TRXC has 6 professional analysts covering the stock, all with buy ratings, and price targets as low as $6.00 per share, and as high as $10.00 per share.
Oct 13 (Reuters) - U.S. FDA -
* FDA clears Senhance System, Transenterix Inc's new robotically-assisted surgical device for adult patients ? Source: (http://bit.ly/2wUfB9N) Further company coverage:
European Society of Gynaecological Oncology
4 Nov - 7 Nov
TransEnterix Schedules Third Quarter 2017 Financial and Operating Results Conference Call for November 9, 2017
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- TransEnterix, Inc. (NYSE American:TRXC) announced today that it plans to release third quarter 2017 financial and operating results after the market closes on Thursday, November 9, 2017. Todd M. Pope, President and Chief Executive Officer, and Joseph P. Slattery, Executive Vice President and Chief Financial Officer will host a conference call to discuss these results starting at 4:30 pm Eastern Time the same day. The call will be concurrently webcast.
To listen to the conference call on your telephone, please dial (844) 804-5261 for domestic callers and (612) 979-9885 for international callers, and reference conference ID 8898746 approximately ten minutes prior to the start time. To access the live audio webcast or archived recording, use the following link http://ir.transenterix.com/events.cfm. The replay will be available on the Company's website.
AAGL Global Congress 2017 TransEnterix, Inc. (NYSE MKT:TRXC) announced today (31/10/2017) that Todd M. Pope, President and Chief Executive Officer, and Joseph P. Slattery, Executive Vice President and Chief Financial Officer, will present at the Stifel 2017 Healthcare Conference at The Lotte New York Palace Hotel in New York, New York. The presentation is scheduled to take place at 5:00 PM Eastern Time on Tuesday, November 14, 2017.
National Harbor, MD
12 Nov - 16 Nov
National Harbor, Maryland USA
TransEnterix to Present at the Stifel 2017 Healthcare Conference